AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on

Acute coronary syndrome patients taking AstraZeneca's Brilinta alone suffered fewer bleeding episodes than those taking the drug alongside aspirin, so-called dual platelet therapy. (AstraZeneca)

PHILADELPHIA—AstraZeneca's longtime clot-buster Brilinta has seen some of its shine wear off as other drugs––not the least of which is SGLT2 star Farxiga––have charted a new course. But the British drugmaker still has hopes for its old stalwart, and aspirin-beating bleeding data in acute coronary syndrome (ACS) could help. 

Solo Brilinta beat out a Brilinta-aspirin combo on the safety side, reducing clinically relevant bleeding while matching up on efficacy. The results came after 12 months in ACS patients who underwent a percutaneous coronary intervention with at least one stent.

Those data were presented Saturday at the American Heart Association's Scientific Sessions as part of a subgroup analysis from Brilinta's phase 3 Twilight trial. On top of beating out dual-platelet therapy in reduced bleeding, solo Brilinta stood up to the Brilinta-aspirin combo in adverse CV events, including all-cause death, heart attacks and stroke. 

The subanalysis included 64% of the Twilight trial population. Following a three-month open-label period treating patients with Brilinta and aspirin, 4,614 patients free of ischemic events and bleeding were continued on either solo Brilinta or the Brilinta-aspirin combo. 

Patients treated with solo Brilinta posted a 53% relative risk reduction in types 2, 3 and 5 bleeding after one year, according to the Bleeding Academic Research Consortium ratings. Specifically in types 3 and 5, Brilinta alone posted a 64% relative risk reduction over the dual therapy. 

Naeem Khan, AstraZeneca's medical VP of cardiovascular and metabolic disease, said the newest data challenged a more than 20-year-old standard of dual-platelet therapy in treating ACS. 

"This is a paradigm shift in thinking about dual therapy," Khan said. 

RELATED: AstraZeneca's Brilinta wins in diabetic artery disease patients

The subanalysis helps builds Brilinta's case for ACS patients after the completion of its Twilight trial studying Brilinta as an add-on to aspirin in treating the syndrome. 

Back in February, Brilinta added to aspirin slashed the combined risk of heart attack, stroke and cardiovascular death in patients with Type 2 diabetes with coronary artery disease who hadn’t suffered a prior heart attack or stroke. The combination topped aspirin alone in the 19,000-plus patient trial, a phase 3 study dubbed Themis.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.